Search

Search Constraints

You searched for: Author/Creator Clavio, Marino

Search Results

1. A blastic plasmacytoid dendritic cell neoplasm‐like phenotype identifies a subgroup of npm1‐mutated acute myeloid leukemia patients with worse prognosis. Issue 2 (17th November 2017)

2. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. (November 2019)

3. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes. Issue 8 (August 2015)

4. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes. Issue 8 (August 2015)

5. Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. Issue 1 (2nd January 2020)

6. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. (23rd January 2018)

7. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk‐oriented consolidation: A critical review of a 10‐year, single‐center experience in younger, non M3 AML patients. Issue 8 (15th June 2016)

8. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems. Issue 10 (29th July 2017)

9. Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD‐driven salvage approach. (26th July 2019)

10. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Issue 12 (19th March 2021)